Multiple SCCs arising in the gluteal area from patient with short disease duration of hidradenitis suppurativa (hurley I‐II): Surgical approach with favorable outcome

2020 ◽  
Vol 33 (3) ◽  
Author(s):  
Valeri Malev ◽  
Torello Lotti ◽  
Georgi Tchernev
Keyword(s):  
Surgical Approach ◽  
Hidradenitis Suppurativa ◽  
Disease Duration ◽  
Favorable Outcome ◽  
Short Disease Duration

Intermammary Hidradenitis Suppurativa: Considerations on a Unique Presentation

2021 ◽  
pp. 1-4
Author(s):  
Ana Luísa João ◽  
Nélia Cunha ◽  
Joana Cabete
Keyword(s):  
Surgical Approach ◽  
Inflammatory Disease ◽  
Pilonidal Sinus ◽  
Hidradenitis Suppurativa ◽  
Chronic Inflammatory Disease ◽  
Pilonidal Sinus Disease ◽  
Sinus Disease ◽  
Case Presentation ◽  
Overweight Women

Introduction: Hidradenitis suppurativa (HS) is a potentially disabling chronic inflammatory disease. The intermammary location, not clearly specified in the usual phenotypic classifications, entails significant functional and cosmetic compromise. Case Presentation: Eleven cases of predominantly intermammary disease with multiple fistulization and disfiguring scarring were observed at our Department between January 2016 and March 2020. They were young (mean age = 22 years) obese or overweight women, in which the medical-surgical approach has led to variable results. Discussion/Conclusion: Intermammary HS possibly represents a unique phenotypic presentation, likely to be fistulizing and severe. We believe that anatomo-functional considerations, which can be paralleled to pilonidal sinus disease, contribute to its pathophysiology and striking appearance, and further emphasize the importance of multidisciplinary endeavor to reduce the morbidity associated with this seemingly overlooked location.

SAT0060 Best Chance of Achieving Remission in RA Patients with Very Short Disease Duration:

2014 ◽  
Vol 73 (Suppl 2) ◽  
pp. 611.1-611
Author(s):  
T. Uhlig ◽  
V. Norvang ◽  
E. Lie ◽  
E. Rødevand ◽  
K. Mikkelsen ◽  
...  
Keyword(s):  
Disease Duration ◽  
Short Disease Duration

scholarly journals Activity of kallikrein-kinin system at patients with asiderotic anemia

2004 ◽  
Vol 3 (2) ◽  
pp. 56-61
Author(s):  
N. N. Zhilkova
Keyword(s):  
Disease Duration ◽  
Proteinase Inhibitors ◽  
Stable State ◽  
Continuous Treatment ◽  
Kinin System ◽  
Α2 Macroglobulin ◽  
Short Disease Duration ◽  
Severity Of The Disease ◽  
Kallikrein Kinin System ◽  
Severity Degree

The aim of investigation is to study the state of kallikrein-kinin system (KKS) and proteinase inhibitors at patients with asiderotic anemia prior to and after the treatment. 58 patients with asiderotic anemia prior to the treatment and in dynamics after 3 weeks have been examined. KKS state has been estimated by kallikrein, prekallikrein, proteinase α1-inhibitor (Pα1I) and α2-macroglobulin (α2-MG) levels in blood plasma having been investigated by Paskhina’s et al.chromatographic method and by Nartikova’s and Paskhina’s unified enzymatic method.Patients with asiderotic anemia had the rise of KKS activity. Its change differences depending on the disease duration have been revealed. At short disease duration a regulated KKS activation and its stable state have been marked. After the treatment at patients with medium severity degree it happens a normalization of all KKS parameters, at patients with serious anemia the high activity of Pα1I persists. The continuous treatment of anemia has led to the development of pathological type activation that had persisted at patients after the treatment.It has been revealed that the degree of KKS activation intensity and its renewal after the implemented treatment depended on the duration and severity of the disease.

Adolescent-Onset Hidradenitis Suppurativa: Prevalence, Risk Factors and Disease Features

Dermatology ◽  
2018 ◽  
Vol 235 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Alejandro Molina-Leyva ◽  
Carlos Cuenca-Barrales
Keyword(s):  
Risk Factors ◽  
Family History ◽  
Hidradenitis Suppurativa ◽  
Disease Duration ◽  
Positive Family History ◽  
Cross Sectional Study ◽  
Cross Sectional ◽  
Female Sex ◽  
Potential Risk Factors ◽  
Sex Positive

Background/Aims: Hidradenitis suppurativa (HS) is a chronic inflammatory and destructive skin disorder. Early diagnosis and treatment are critical to stop its progression. Data concerning adolescent-onset HS are scarce. The aims of this study are to describe the prevalence of adolescent-onset HS and to explore potential risk factors and the disease features of these patients. Patients and Methods: A cross-sectional study including 134 patients was performed. Results: Adolescent-onset HS occurred in 51.5% (69/134) of patients. Adolescent-onset HS was associated with female sex, positive family history, presence of pilonidal sinus, acne conglobata, longer disease duration and a worse perception of disease severity. Conclusion: Adolescent-onset HS might be more frequent than previously reported. Female sex, positive family history and the presence of elements of the follicular occlusion tetrad identify individuals with a higher risk of early onset. These patients experience a longer disease duration and perceive their disease as severer.

Inframammary Hidradenitis Suppurativa: An optimal surgical approach to a challenging region

2020 ◽  
Vol 26 (11) ◽  
pp. 2312-2313
Author(s):  
Eran Shavit ◽  
Afsaneh Alavi ◽  
Ralph George
Keyword(s):  
Surgical Approach ◽  
Hidradenitis Suppurativa

How to better help cancer patients face their coming death?

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e21505-e21505 ◽  
Author(s):  
Francois-Xavier Goudot ◽  
Milena Maglio ◽  
Sandrine Bretonniere
Keyword(s):  
Palliative Care ◽  
Cancer Patients ◽  
Disease Duration ◽  
Hospice Care ◽  
Good Practice ◽  
Terminal Phase ◽  
Palliative Care Teams ◽  
Short Disease Duration ◽  
Impending Death ◽  
The Mean

e21505 Background: According to literature and medical experience, the doctor-patient relationship becomes strained when oncologists tell their patients that they have no more curative treatments to offer them. Patients often resist when they are told that it is in their best interest to meet with the palliative teams. Little is known about how to meet patients’ expectations at this advanced stage. Methods: We conducted a multicenter qualitative research in an oncology department, a hospital at home service and in an inpatient hospice care center. We met 47 patients (M = 21, F = 27, mean age = 65 yrs, mean disease duration = 5 yrs) for in-depth face to face interviews performed by a multi-disciplinary ethics team. Interviews were carried out between 1 and 3 months before death. Results: Qualitative analysis revealed 4 main results. 1/ For respondents, palliative care introduction meant impending death. 2/ Palliative care introduction meant loss of hope. Without hope, the cancer trajectory is impossible to sustain, they said. 3/ Hope was intricately interwoven with the request for more chemotherapy, even if doctors had clearly refused to provide it. 4/ The oncologist remained the referent physician, even for patients in hospice care. Patients for which the mean duration between cancer diagnosis and interview was 5 years or more, were more willing to talk about death and better accepted palliative care than patients for which the mean duration of cancer was inferior to 3 yrs. For patients with fast progressing cancer (n = 11), 10 were not willing to talk about death and 7 strongly resisted palliative care introduction. There was no difference between patients according to age, sex, type of cancer or center of inclusion. Conclusions: In the terminal phase of cancer, patients are unwilling to talk about death and are reluctant to meet with palliative care teams. Short disease duration strongly reinforces this attitude. If patients resist discussions about their impending death, should physicians continue to consider it good practice to introduce such discussions? Is it beneficent for patients?

scholarly journals Phenotyping Individuals With Newly-Diagnosed Type 2 Diabetes at Risk for All-Cause Mortality: A Single Centre Observational, Prospective Study

2020 ◽  
Author(s):  
Edoardo Biancalana ◽  
Federico Parolini ◽  
Alessandro Mengozzi ◽  
Anna Solini
Keyword(s):  
Type 2 Diabetes ◽  
Mortality Rate ◽  
Disease Duration ◽  
Previous History ◽  
Newly Diagnosed ◽  
Time Data ◽  
Short Disease Duration ◽  
All Cause Mortality

Abstract Background Type 2 diabetes (T2D) shows a high mortality rate, dependent on disease duration, comorbidities and glucose control over time. Data on patients with short disease duration are scanty.Methods We prospectively followed a cohort of newly-diagnosed T2D patients referring to a single diabetes centre, treated according to the international guidelines and checked every 6-12 months. All-cause mortality and major cardiovascular (CV) events were registered.Results 289 patients out of 3019 consecutive first attendances matched inclusion criteria and were included in the observation. Mean follow-up was 51.2 months. At 31 December 2018, 253 patients were alive and 36 deceased. At baseline, deceased individuals were older, with lower eGFR and lower uric acid, higher prevalence of atrial fibrillation. During the follow-up, 18 non-fatal CV events were adjudicated; patients with incident CV disease (CVD) differed at baseline for sex, previous history of CVD and retinopathy, higher use of secretagogues and lower use of metformin. At multivariate analysis, age and previous CVD were the only independent determinants of all-cause mortality and incident CVD, respectively. In deceased individuals, eGFR slope was markedly unstable and ΔeGFR at the end of the follow-up was higher (p<0.001), and predicted mortality. Conclusion Newly-diagnosed T2D patients followed according to the best clinical practice show a mortality rate similar to that reported in more complicated patients with longer disease duration; none of the clinical and biochemical variables commonly measured at baseline can predict mortality or incident CVD; early metformin use seems to be associated with no risk of prevalent or incident retinopathy.

scholarly journals Phenotyping Individuals With Newly-Diagnosed Type 2 Diabetes at Risk for All-Cause Mortality: A Single Centre Observational, Prospective Study

2020 ◽  
Author(s):  
Edoardo Biancalana ◽  
Federico Parolini ◽  
Alessandro Mengozzi ◽  
Anna Solini
Keyword(s):  
Type 2 Diabetes ◽  
Mortality Rate ◽  
Disease Duration ◽  
Previous History ◽  
Newly Diagnosed ◽  
Time Data ◽  
Short Disease Duration ◽  
All Cause Mortality

Abstract Background Type 2 diabetes (T2D) shows a high mortality rate, dependent on disease duration, comorbidities and glucose control over time. Data on patients with short disease duration are scanty. Methods We prospectively followed a cohort of newly-diagnosed T2D patients referring to a single diabetes centre, treated according to the international guidelines and checked every 6-12 months. All-cause mortality and major cardiovascular (CV) events were registered. Results 289 patients out of 3019 consecutive first attendances matched inclusion criteria and were included in the observation. Mean follow-up was 51.2 months. At 31 December 2018, 253 patients were alive and 36 deceased. At baseline, deceased individuals were older, with lower eGFR and lower uric acid, higher prevalence of atrial fibrillation. During the follow-up, 18 non-fatal CV events were adjudicated; patients with incident CV disease (CVD) differed at baseline for sex, previous history of CVD and retinopathy, higher use of secretagogues and lower use of metformin. At multivariate analysis, age and previous CVD were the only independent determinants of all-cause mortality and incident CVD, respectively. In deceased individuals, eGFR slope was markedly unstable and ΔeGFR at the end of the follow-up was higher (p<0.001), and predicted mortality. Conclusion Newly-diagnosed T2D patients followed according to the best clinical practice show a mortality rate similar to that reported in more complicated patients with longer disease duration; none of the clinical and biochemical variables commonly measured at baseline can predict mortality or incident CVD; early metformin use seems to be associated with no risk of prevalent or incident retinopathy.

Sign in / Sign up

Export Citation Format

Share Document